Mathai Michael L, Chen Nora, Cornall Lauren, Weisinger Richard S
School of Biomedical and Health Sciences, Victoria University, Melbourne, Australia.
Endocr Metab Immune Disord Drug Targets. 2011 Sep 1;11(3):198-205. doi: 10.2174/187153011796429853.
Obesity is associated with increased body fat composition and elevated risk of metabolic and cardiovascular disease. The activity of the renin-angiotensin system is generally increased in obesity and experimental evidence has shown that angiotensin influences appetite and metabolism as well as mechanisms that induce adipose tissue growth and metabolism in peripheral organs. This review summarises some of the key evidence from animal and human experiments that links the renin-angiotensin system to obesity and metabolic disease. This research has been greatly aided by the continuing development of new pharmaceuticals that inhibit the renin-angiotensin system. While their primary use is in the treatment of hypertension and heart failure, a range of experimental and clinical evidence indicates their potential use in the treatment of obesity and metabolic disease.
肥胖与体脂成分增加以及代谢和心血管疾病风险升高有关。肾素-血管紧张素系统的活性在肥胖状态下通常会增强，实验证据表明，血管紧张素会影响食欲和新陈代谢，以及诱导外周器官脂肪组织生长和代谢的机制。本综述总结了来自动物和人体实验的一些关键证据，这些证据将肾素-血管紧张素系统与肥胖和代谢疾病联系起来。新型抑制肾素-血管紧张素系统的药物不断研发，极大地推动了这项研究。虽然它们的主要用途是治疗高血压和心力衰竭，但一系列实验和临床证据表明它们在治疗肥胖和代谢疾病方面具有潜在用途。
